Odatroltide demonstrated potential in reperfusion-ineligible AIS patients, who currently face significant unmet medical needs.

NEW ORLEANS -- Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, ...

For infants and toddlers who have had a stroke, a new treatment that restricted the use of their stronger arm and hand to encourage them to use their stroke-affected arm and hand, combined with ...

Chamorro argued that the apparent difference in mortality likely reflects an "extremely low" event rate among control ...

A smartwatch app designed to measure social interactions of hospitalized stroke survivors may enable new treatments to preserve or enhance cognition, social engagement and quality of life after a ...

Court upholds injunction against NIH funding cuts Cuts targeted federal research funding at major universities Policy violated NIH regulations and congressional funding language, court rules BOSTON, ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Walter Koroshetz, director of the National Institute of Neurological Disorders and ...

SINGAPORE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- In a pioneering advancement that aims to reduce the increasing problem of strokes, PT Kalbe Farma Tbk - the largest publicly listed pharmaceutical company ...

Dec 3 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up ...

A study found that NIH grant cuts under the Trump administration in 2025 have already led to the termination of 118 trials studying cancer, 97 studying infectious diseases and 140 testing new ...

CLINICAL QUESTION: Does an updated National Institutes of Health Stroke Scale (NIHSS) language assessment tool perform well in a sample of diverse, neurologically unimpaired English-speaking adults?

Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and ...